Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories

Insiders have been trading these 5 stocks: (($APLD)), (($GS)), (($UPS)), (($ABT)) and (($SLB)). Here is a breakdown of their recent trades and thei...

Applied Digital, Goldman Sachs, UPS, Abbott, Schlumberger Shake-Up

Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories today and set a price target of $169.00. Miksic covers the Healthcare s...

Abbott Laboratories (ABT) Gets a Buy from Barclays

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intuitive Surgical (ISRG – Research Report) and Abbott Laboratori...

Analysts Conflicted on These Healthcare Names: Intuitive Surgical (ISRG) and Abbott Laboratories (ABT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), Maravai...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX)

In a report released today, Vijay Kumar from Evercore ISI maintained a Buy rating on Abbott Laboratories, with a price target of $138.00. Kumar cov...

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Traders seeking the most recent earnings reports, analyst updates, deals, and other news will find them in the TipRanks daily wrap-up.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Simu...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Simulations Plus (SLP)

Abbott Laboratories’ ($ABT) shares came down with a fever early Thursday after the American healthcare company posted sales growth for its fourth q...

ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and BioC...

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

If building a dependable income portfolio is on your radar for 2026, dividend aristocrat stocks offer a compelling way to secure a consistent strea...

3 Best Dividend Aristocrat Stocks to Buy Now, 01/21/2026

Investors looking for undervalued stocks in the current volatile market may want to pay close attention to Wall Street’s latest picks. These stocks...

3 Best Value Stocks with Over 30% Upside in 2026, According to Analysts 

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Teli...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Telix Pharmaceuticals (OtherTLPPF)

This week, several major companies will be reporting earnings. Among them are Intel (INTC), Netflix (NFLX), Johnson & Johnson (JNJ), GE Aerospace (...

Options Volatility and Implied Earnings Moves This Week, January 20 – January 23, 2026

U.S. stocks finished the week essentially flat as a semiconductor-led bid was offset by softer bank performance and a steady drumbeat of policy hea...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 18

Exchange-traded funds (ETFs) offer investors a broad and often daunting array of options. TipRanks’ AI analysts pare this universe down to three ET...

3 Best ETFs to Invest In, According to AI Analyst, 01/12/2026

U.S. stocks ended the week higher as investors balanced softer hiring data with new government support for housing and stronger momentum in energy ...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 11

In a report released on January 7, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Abbott Laboratories, with a price target of $147...

RBC Capital Remains a Buy on Abbott Laboratories (ABT)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories, with a price target of $169.00. According to ...

Current Quarter	$1.15	Next Quarter	$1.38
Current Year	$5.68	Next Year	$6.23
QoQ Growth	+20.0%	YoY Growth	+9.7%
3Y EPS CAGR	+24.6%	Target Price	$137.54
Consensus	Buy	Upside	+26.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABT	$108.78	-0.58%	8.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABT	$108.78	-0.6%	8.44M
3
4
5
6

ABT

ABT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Abbott Laboratories Data in Excel

Get Abbott Laboratories Data in Excel